Hemophilia B" />
Korean J Hematol 2008; 43(3):
Published online September 30, 2008
https://doi.org/10.5045/kjh.2008.43.3.179
© The Korean Society of Hematology
박영실 유기영
경희대학교 의과대학 소아과학교실,
한국혈우재단의원
Among the patients with hemophilia, 10∼15% have hemophilia B, and 1∼3% of the hemophilia B patients develop inhibitor to factor IX clotting activity. Allergic reactions to concentrates containing factor IX (FIX) are serious complications during the treatment of hemophilia B patients with inhibitor. Although treatment with recombinant activated factor VII (FVIIa) is generally recommended in these patients, it is limited by the agent's short half-life, a lack of experience with its use in this manner and the prohibitive cost. We report here on a case of a 9-year-old boy with severe hemophilia B with inhibitor and he had a history of anaphylaxis to FIX. The patient was successfully treated with a desensitization protocol with escalating doses of FIX in addition to administering premedications. (Korean J Hematol 2008;43: 179-183.)
Keywords Hemophilia B, Inhibitor, Anaphylaxis, Desensitization
Korean J Hematol 2008; 43(3): 179-183
Published online September 30, 2008 https://doi.org/10.5045/kjh.2008.43.3.179
Copyright © The Korean Society of Hematology.
박영실 유기영
경희대학교 의과대학 소아과학교실,
한국혈우재단의원
Young shil Park, Ki Young Yoo
Department of Pediatrics, Colllege of Medicine, Kyung Hee University, Korea Hemophilia Foundation, Seoul, Korea
Among the patients with hemophilia, 10∼15% have hemophilia B, and 1∼3% of the hemophilia B patients develop inhibitor to factor IX clotting activity. Allergic reactions to concentrates containing factor IX (FIX) are serious complications during the treatment of hemophilia B patients with inhibitor. Although treatment with recombinant activated factor VII (FVIIa) is generally recommended in these patients, it is limited by the agent's short half-life, a lack of experience with its use in this manner and the prohibitive cost. We report here on a case of a 9-year-old boy with severe hemophilia B with inhibitor and he had a history of anaphylaxis to FIX. The patient was successfully treated with a desensitization protocol with escalating doses of FIX in addition to administering premedications. (Korean J Hematol 2008;43: 179-183.)
Keywords: Hemophilia B, Inhibitor, Anaphylaxis, Desensitization
Novie A. Chozie, Djajadiman Gatot, Bambang Sudarmanto, Susi Susanah, Rini Purnamasari, Pudjo Hagung Widjajanto, Susanto Nugroho, Olga Rasiyanti, Dian Puspitasari, Muhammad Riza, Maria C. Shanty Larasati, Sri Suryo Adiyanti, Made Citra Saraswati, Fitri Primacakti, on behalf of the Pediatric Hematology-Oncology Working Group of the Indonesian Pediatric Society
Blood Res 2022; 57(4): 272-277Ju Young Kim, Chur Woo You
Blood Res 2019; 54(3): 204-209Dong Il Won, Sujeong Kim, and Eun Hee Lee
Blood Res 2018; 53(4): 299-306